Dean Capital Management Makes New $2.52 Million Investment in Prestige Consumer Healthcare Inc. $PBH

Dean Capital Management acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 40,899 shares of the company’s stock, valued at approximately $2,523,000. Prestige Consumer Healthcare accounts for 1.1% of Dean Capital Management’s portfolio, making the stock its 26th biggest holding.

Several other large investors also recently added to or reduced their stakes in PBH. Norges Bank purchased a new stake in Prestige Consumer Healthcare in the fourth quarter valued at approximately $36,954,000. Nordea Investment Management AB grew its stake in Prestige Consumer Healthcare by 547.4% in the 4th quarter. Nordea Investment Management AB now owns 615,215 shares of the company’s stock worth $37,811,000 after buying an additional 520,186 shares in the last quarter. Brandes Investment Partners LP increased its holdings in shares of Prestige Consumer Healthcare by 93.2% in the 4th quarter. Brandes Investment Partners LP now owns 606,737 shares of the company’s stock worth $37,430,000 after buying an additional 292,744 shares during the last quarter. Capital Research Global Investors increased its holdings in shares of Prestige Consumer Healthcare by 107.9% in the 4th quarter. Capital Research Global Investors now owns 561,497 shares of the company’s stock worth $34,639,000 after buying an additional 291,425 shares during the last quarter. Finally, Squarepoint Ops LLC increased its holdings in shares of Prestige Consumer Healthcare by 316.1% in the 3rd quarter. Squarepoint Ops LLC now owns 301,866 shares of the company’s stock worth $18,836,000 after buying an additional 229,311 shares during the last quarter. Institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH opened at $46.99 on Friday. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of 12.02, a PEG ratio of 1.48 and a beta of 0.35. The business has a 50 day moving average of $51.43 and a 200 day moving average of $59.24. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $85.29.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 EPS for the quarter, missing analysts’ consensus estimates of $1.39 by ($0.16). The business had revenue of $281.62 million for the quarter, compared to the consensus estimate of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The firm’s revenue was down 5.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.32 earnings per share. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, sell-side analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PBH has been the topic of several research reports. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Canaccord Genuity Group reduced their target price on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, May 14th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare presently has a consensus rating of “Hold” and an average price target of $70.75.

Insider Activity

In other news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total value of $66,372.93. Following the completion of the sale, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).